Skip to main content

Table 1 Studies utilizing BLT-humanized mice for evaluating HIV-therapeutics

From: Moving beyond the mousetrap: current and emerging humanized mouse and rat models for investigating prevention and cure strategies against HIV infection and associated pathologies

StrategyTherapeutic agent(s)Reference(s)
Antiviral therapydCA[45, 56]
EFdA[57]
RAL[45]
PD-1 mAb[58]
PG16 bNAb[59]
PGT121 bNAb[60]
3TC, TDF[61]
AZT, ddI, IDV[52]
FTC, RPV, DTG[46, 57]
FTC, TAF, EVG[62]
FTC, TDF, DTG[37, 46, 51, 53, 63]
FTC, TDF, RAL[37, 46, 51, 63]
FTC, TDF, RAL, 3B3(Fv)-PE38 immunotoxin[64]
FTC, TDF, RAL, IFNα14[61, 65]
Pre-exposure prophylaxis (PrEP)C5A peptide[66]
 Cc-griffithsin[67]
 CD4 AsiCs[68]
 CD4-expressing Lactobacillus acidophilus[69]
 CD4mc P-III-48[70]
 DTG-ultra LA[71]
 EFdA[72]
 G2-S16 PCD[73]
 IgA[74]
 MVC[75]
 RAL-LA[76]
 RPV-LA[39, 77]
 siCCR5 LFA-1 I-tsNP[78]
 TNV gel[79,80,81]
 VRC01 bNAb[82]
 FTC, TAF[83]
 FTC, TDF[36, 43, 84, 85]
 TAF, EVG[86]
 b12, VRC01, VRC07 G54W bNAbs[87]
Latency-reversing agents (LRAs)AZD5582[88]
panobinostat[89]
SUW133 (bryostatin analog)[90]
VaccinesPLGA-Gag microparticles[49, 91]
Recombinant GP140∆683[49, 91]
Proviral excisionsaCas9/sgRNA[92]
T cell engineeringCCR5 shRNA[93, 94]
CD4 CAR[95]
3TC, lamivudine; AsiCs, aptamer-siRNA chimeras; AZT, zidovudine; bNAb, broadly neutralizing antibody; CCR5, C–C chemokine receptor type 5; CAR, chimeric antigen receptor; CD4, cluster of differentiation 4; CD4mc, CD4 mimetic compound; Cc, Caulobacter crescentus recombinant expressing; dCA, didehydro-Cortistatin A; ddI, didanosine; DTG, dolutegravir; DTG-ultra LA, long acting dolutegravir; EFdA, 4′-ethynyl-2-fluoro-2′-deoxyadeno-sine; EVG, elvitegravir; FTC, emtricitabine; IDV, indinavir; IFNα14, interferon α suptype 14; IgA, immunoglobulin A; LFA-1 I-tsNP, lymphocyte function–associated antigen-1 integrin-targeted and stabilized nanoparticle; mAb, monoclonal antibody; MVC, maraviroc; PCD, polyanionic carbosilane dendrimers; PD-1, programmed cell death protein 1; PLGA, poly(lactic-co-glycolic) acid; RAL, raltegravir; RAL-LA, long-acting raltegravir; RPV, rilpivirine; RPV-LA, long acting rilpivirine; saCas9/sgRNA, Staphylococcus aureus CRISPR-associated protein 9/single-guide RNA; shRNA, short hairpin RNA; siCCR5, small interfering RNA CCR5; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TNV; tenofovir